Prognostic value of matrix metalloproteinases in patients with anthracycline-induced heart failure

Highlights . Elevated levels of matrix metalloproteinases 2 and 9 are associated with the initiation severity CHF developed after breast cancer therapy anthracyclines, which may contribute to cardiac remodeling progression systolic dysfunction. Concentrations metalloproteinases-2 -9 in blood serum serve as predictors unfavorable course anthracycline-induced heart failure. Aim To assess role (MMP-2) (MMP-9) development chronic failure (CHF) during 24 months observation. Methods The study included 114 women 12 completion chemotherapy (CT) for CHF. control group (n = 70) consisted (mean age 45.0 [42.0; 50.0] years old) who received doxorubicin part chemotherapy, but they did not develop chemotherapy. biomarkers (MMP-2, MMP-9, NT-proBNP) were determined using a sandwich immunoassay. Results Patients had signs higher values NT-proBNP, MMP-2 MMP-9 (p<0.001) than from group. After observation, all patients divided into groups: 1 – an 54), favorable pathology 60). Criteria CHF: emergence new or worsening existing symptoms/signs failure; and/or hospitalization due HF decompensation; decrease left ventricular ejection fraction by more 10%; increase functional class more. Baseline echocardiographic parameters NT-proBNP differ groups 2. Levels 8% (p 0.017) 18.4% 1. In level decreased increased end observation period. ≥388.2 pg/ml (sensitivity 46%, specificity 80%; AUC 0.64; p 0.013) ≥21.3 86%, 84.4%; 0.9; p<0.001) Conclusion Remodeling extracellular play important pathogenesis initiated drugs anthracycline class. can be recommended when assessing risk pathology.